Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
28 sept. 2022 07h12 HE
|
Resverlogix Corp
CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19...